CCL2 and myocardial infarction: Ohnishi et al.42 discovered that the application of MSCs to a rat model of MI could reduce the levels of CD68-positive inflammatory cells and monocyte chemotactic protein-1 (MCP-1) in the myocardium, thereby improving cardiac function.